Proceedings of a Consensus Conference: Pathogen Inactivation-Making Decisions About New Technologies

Transfusion Medicine Reviews

Volumn 22, Issue 1, 2008, Pages 1-34

  Webert, Kathryn E ^a,b   Cserti, Christine M ^a,b   Hannon, Judy ^a,b   Lin, Yulia ^a,b   Pavenski, Katerina ^a,b   Pendergrast, Jacob M ^a,b   Blajchman, Morris A ^a,b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT;

ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; CLINICAL DECISION MAKING; COST BENEFIT ANALYSIS; ECONOMIC EVALUATION; ERYTHROCYTE; ETHICS; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEALTH SURVEY; HEMATOLOGICAL PROCEDURES; HEMOLYSIS; HUMAN; NONHUMAN; PLASMA INACTIVATION; PUBLIC HEALTH PROBLEM; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY;

ANIMALS; ANTI-INFECTIVE AGENTS; BLOOD PLATELETS; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; CLINICAL LABORATORY TECHNIQUES; COST-BENEFIT ANALYSIS; DECISION MAKING; ERYTHROCYTES; EUROPE; HUMANS; MICROBIAL VIABILITY; PUBLIC HEALTH; TECHNOLOGY, MEDICAL; TRANSPLANTATION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 36649022874     PISSN: 08877963     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmrv.2007.09.001     Document Type: Article

References (106)

1. Klein H.G., Anderson D., Bernardi M.J., et al. Pathogen inactivation: making decisions about new technologies-Preliminary report of a consensus conference. Vox Sang 93 (2007) 179-182
2. Busch M.P. Transfusion-transmitted viral infections: Building bridges to transfusion medicine to reduce risks and understand epidemiology and pathogenesis. Transfusion 46 (2006) 1624-1640
3. Murphy W. Managing threats rather than risks in blood transfusion: Robust design for a complex system. Transfusion 46 (2006) 2011-2013
4. Gubler D.J. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11 (1998) 480-496
5. Stramer S.L., Fang C.T., Foster G.A., et al. West Nile virus among blood donors in the United States, 2003 and 2004. N Engl J Med 353 (2005) 451-459
6. Klein H.G., Dodd R.Y., Dzik W.H., et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 38 (1998) 102-107
7. Bryant B.J., and Klein H.G. Pathogen inactivation: The definitive safeguard for the blood supply. Arch Pathol Lab Med 131 (2007) 719-733
8. Wagner S.J. Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 16 (2002) 61-66
9. Hanson C.V. Photochemical inactivation of viruses with psoralens: an overview. Blood Cells 18 (1992) 7-25
10. Grass J.A., Hei D.J., Metchette K., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 91 (1998) 2180-2188
11. Ennever J.F., and Speck W.T. Short communication. Photochemical reactions of riboflavin: Covalent binding to DNA and to poly (dA). poly (dT). Pediatr Res 17 (1983) 234-236
12. Ito K., Inoue S., Yamamoto K., et al. 8-Hydroxydeoxyguanosine formation at the 5′ site of 5′-GG-3′ sequences in double-stranded DNA by UV radiation with riboflavin. J Biol Chem 268 (1993) 13221-13227
13. Corash L. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apheresis Sci 25 (2001) 179-181
14. Purmal A., Valeri C.R., Dzik W., et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: Preclinical studies. Transfusion 42 (2002) 139-145
15. McQueen C.A., Devito M., Chapin R., et al. Definition of toxicology. Society of Toxicology web site. http://www.toxicology.org/ai/pub/si05/SI05_Define.asp [accessed August 27, 2007]
16. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: A clinical perspective. Semin Hematol 38 (2001) 12-19
17. Ciaravino V., McCullough T., and Cimino G. The role of toxicology assessment in transfusion medicine. Transfusion 43 (2003) 1481-1492
18. Chapman J.R., Moore K., and Butterworth B.E. Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion 43 (2003) 1386-1393
19. Ciaravino V., McCullough T., Cimino G., et al. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sang 85 (2003) 171-182
20. Ciaravino V., McCullough T., and Dayan A.D. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 20 (2001) 533-550
21. Butterworth B.E., and Chapman J. Exposure of hematopoietic stem cells to ethylene oxide during processing represents a potential carcinogenic risk for transplant recipients. Regul Toxicol Pharmacol (2007) [E-publication 01 Aug 2007]
22. Horowitz B., Bonomo R., Prince A.M., et al. Solvent/detergent-treated plasma: A virus-inactivated substitute for fresh frozen plasma. Blood 79 (1992) 826-831
23. Biesert L., and Suhartono H. Solvent/detergent treatment of human plasma-A very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 74 (1998) 207-212 [Suppl 1]
24. Lin L., Cook D.N., Wiesehahn G.P., et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 37 (1997) 423-435
25. Lambrecht B., Mohr H., Knuver-Hopf J., et al. Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 60 (1991) 207-213
26. Goodrich R.P. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 78 (2000) 211-215 [Suppl 2]
27. Flamholz R., Jeon H.R., Baron J.M., et al. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?. J Clin Apheresis 15 (2000) 169-172
28. Coignard B., Nguyen G.T., Tokars J., et al. A cluster of intra-operative deaths in a liver transplant center associated with the use of solvent/detergent plasma. [abstract]. Proceedings of the 11th Annual Meetings of the Society for Healthcare Epidemiology of America (2001)
29. Yarranton H., Cohen H., Pavord S.R., et al. Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121 (2003) 778-785
30. Williamson L.M., Llewelyn C.A., Fisher N.C., et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 39 (1999) 1227-1234
31. Williamson L.M., and Llewelyn C.A. Efficacy of SD-treated plasma during liver transplantation (reply). [letter]. Transfusion 40 (2000) 887-888
32. Salge-Bartels U., Breitner-Ruddock S., Hunfeld A., et al. Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe?. Transfus Med 16 (2006) 266-275
33. Heger A., Romisch J., and Svae T.E. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment. Transfus Apheresis Sci 35 (2006) 223-233
34. Hellstern P. Solvent/detergent-treated plasma: Composition, efficacy, and safety. Curr Opin Hematol 11 (2004) 346-350
35. Stanworth S.J., Brunskill S.J., Hyde C.J., et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 126 (2004) 139-152
36. Simonsen A.C., and Sorensen H. Clinical tolerance of methylene blue virus-inactivated plasma. A randomized crossover trial in 12 healthy human volunteers. Vox Sang 77 (1999) 210-217
37. Wieding J.U., et al. Prospective randomized and controlled trial on solvent/detergent plasma versus methylene blue light inactivated plasma. [abstract]. Transfusion 39 (2007) 23S [Suppl]
38. Varez-Larran A., Del R.J., Ramirez C., et al. Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Vox Sang 86 (2004) 246-251
39. de la R.J., Arriaga F., Linares D., et al. Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura. Br J Haematol 114 (2001) 721-723
40. del Rio-Garma J., Alvarex-Larran A., Martinez C., et al. Methylene blue photoinactivated plasma (MBPIP) vs fresh frozen plasma (FFP) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP): a multicentre prospective-cohort study. [abstract]. Vox Sang 93 (2007) 41 [suppl 1]
41. Atance R., Pereira A., and Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 41 (2001) 1548-1552
42. Osselaer J.C., Debry C., Goffaux M., et al. Coagulation function in fresh frozen plasma prepared with two photochemical treatment methods. [abstract]. Vox Sang 91 (2006) 183 [Suppl 3]
43. Politis C., Kavallierou L., Hantziara S., et al. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 92 (2007) 319-326
44. Pehta J.C. Clinical studies with solvent detergent-treated products. Transfus Med Rev 10 (1996) 303-311
45. Chekrizova V., and Murphy W.G. Solvent-detergent plasma: Use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 16 (2006) 85-91
46. Mintz P.D., Bass N.M., Petz L.D., et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 107 (2006) 3753-3760
47. Mintz P.D., Neff A., MacKenzie M., et al. A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46 (2006) 1693-1704
48. Jackson B.R., AuBuchon J.P., and Birkmeyer J.D. Update of cost-effectiveness analysis for solvent-detergent-treated plasma. [letter]. JAMA 282 (1999) 329
49. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 39 (1999) 479-487
50. Riedler G.F., Haycox A.R., Duggan A.K., et al. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85 (2003) 88-95
51. Goodrich R.P., Li J., Pieters H., et al. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects. Vox Sang 90 (2006) 279-285
52. AuBuchon J.P., Herschel L., Roger J., et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 45 (2005) 1335-1341
53. Snyder E., Raife T., Lin L., et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 44 (2004) 1732-1740
54. Harker L.A., and Slichter S.J. The bleeding time as a screening test for evaluation of platelet function. N Engl J Med 287 (1972) 155-159
55. Slichter S.J., Raife T.J., Davis K., et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct prolonged bleeding times in patients with thrombocytopenia. Transfusion 46 (2006) 731-740
56. McCullough J., Vesole D.H., Benjamin R.J., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 104 (2004) 1534-1541
57. van Rhenen R.D., Gulliksson H., Cazenave J.P., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 101 (2003) 2426-2433
58. Janetzko K., Cazenave J.P., Kluter H., et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 45 (2005) 1443-1452
59. Pickard C., AuBuchon J.P., Tosteson A.N.A., et al. Influence of gender and collection order on radiolabeled red blood cell recovery. [abstract]. Transfusion 35 (1995) 6S [Suppl]
60. US Food and Drug Administration. Blood Products Advisory Committee transcript. Blood Products Advisory Committee (2004). http://www.fda.gov/OHRMS/DOCKETS/ac/04/transcripts/2004-4057t1.htm [accessed August 27, 2007]
61. AuBuchon J.P., Pickard C.A., Herschel L.H., et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: A phase I clinical study. Transfusion 42 (2002) 146-152
62. Rios J.A., Hambleton J., Viele M., et al. Viability of red cells prepared with S-303 pathogen inactivation treatment. Transfusion 46 (2006) 1778-1786
63. Benjamin R.J., McCullough J., Mintz P.D., et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: A phase III clinical trial in cardiac surgery patients. Transfusion 45 (2005) 1739-1749
64. Wagner S.J. Pathogen inactivation. Presented at AABB Annual Meeting, Seattle, WA (2005)
65. Lublin D.M. Universal RBCs. Transfusion 40 (2000) 1285-1289
66. Garratty G. Progress in modulating the RBC membrane to produce transfusable universal/stealth donor RBCs. Transfus Med Rev 18 (2004) 245-256
67. Garratty G. In vitro reactions with red blood cells that are not due to blood group antibodies: A review. Immunohematol 14 (1998) 1-11
68. Conlan M.G., Stassinopoulos A., Garratty G., et al. Antibody formation to S-303-treated RBCs in setting of chronic RBC transfusion. [abstract]. Blood 104 (2004) 112a [Suppl]
69. North A., Garratty G., Schott M., et al. A modified process for preparation of S-303 RBCs for pathogen inactivation substantially reduces potential for reactivity. [abstract]. Transfusion 46 (2006) 116A [Suppl]
70. Stassinopoulos A., Schott M.A., and Castro G.M. Modification of the S-303 RBC pathogen inactivation process results in normal S-303 RBC viability in rabbits hyper-immunized to S-303 [abstract]. Vox Sang 89 (2005) 138-139 [Supp]
71. Stainsby D., Jones H., Asher D., et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 20 (2006) 273-282
72. Dzik W.H., Murphy M.F., Andreu G., et al. An international study of the performance of sample collection from patients. Vox Sang 85 (2003) 40-47
73. Murphy M.F., Stearn B.E., and Dzik W.H. Current performance of patient sample collection in the UK. Transfus Med 14 (2004) 113-121
74. Figueroa P.I., Ziman A., Wheeler C., et al. Nearly two decades using the check-type to prevent ABO incompatible transfusions: One institution's experience. Am J Clin Pathol 126 (2006) 422-426
75. Cserti C.M., Ward M., and Uhl L. Impact of a policy to use only group O red cell transfusions for recipients with fewer-than-twice established ABO types: A feasible means to reduce potential ABO incompatible transfusion errors. [abstract]. Blood 108 (2006) 289a [Suppl]
76. Denomme G.A., and Van O.M. High-throughput multiplex single-nucleotide polymorphism analysis for red cell and platelet antigen genotypes. Transfusion 45 (2005) 660-666
77. Vostal J. Update on bacterial contamination. Presentation at 2005 AABB Annual Meeting, slide 18 (2005)
78. FDA Center for Drug Evaluation and Research Guidance documents. http://fda.gov/cder/guidance/index.htm#pharmacology/toxicology [Accessed August 27, 2007]
79. Zarbock A., Singbartl K., and Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 116 (2006) 3211-3219
80. Pitchford S.C., Momi S., Giannini S., et al. Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood 105 (2005) 2074-2081
81. Kupatt C., Wichels R., Horstkotte J., et al. Molecular mechanisms of platelet-mediated leukocyte recruitment during myocardial reperfusion. J Leukoc Biol 72 (2002) 455-461
82. Benjamin R.J. Presentation at AABB Annual Meeting (2006)
83. Hanley J.A., and Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 249 (1983) 1743-1745
84. Snyder E., McCullough J., Slichter S.J., et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: The SPRINT trial. Transfusion 45 (2005) 1864-1875
85. Offergeld R., Faensen D., Ritter S., et al. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: Risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 10 (2005) 8-11
86. German haemovigilance, Paul-Ehrlich-Institute. 2007.
87. Schrezenmeier H., Walther-Wenke G., Muller T.H., et al. Bacterial contamination of platelet concentrates: Results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 47 (2007) 644-652
88. Knutson F., Alfonso R., Dupuis K., et al. Photochemical inactivation of bacteria and HIV in buffy-coat-derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 78 (2000) 209-216
89. Sachs U.J., Kauschat D., and Bein G. White blood cell-reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 45 (2005) 1628-1631
90. Solheim B.G., and Seghatchian J. Update on pathogen reduction technology for therapeutic plasma: An overview. Transfus Apheresis Sci 35 (2006) 83-90
91. Custer B. Economic analyses of blood safety and transfusion medicine interventions: A systematic review. Transfus Med Rev 18 (2004) 127-143
92. van Hulst M., De Wolf J.T., Staginnus U., et al. Pharmaco-economics of blood transfusion safety: Review of the available evidence. Vox Sang 83 (2002) 146-155
93. AuBuchon J.P., and Birkmeyer J.D. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 272 (1994) 1210-1214
94. Riedler G.F., Haycox A.R., Duggan A.K., et al. Solvent-detergent-treated plasma may be cost-effective. Vox Sang 84 (2003) 334-335
95. Bell C.E., Botteman M.F., Gao X., et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 25 (2003) 2464-2486
96. Staginnus U., and Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 80 (2004) 317-324
97. Janssen M.P., van der Poel C.L., Buskens E., et al. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 46 (2006) 956-965
98. Postma M.J., van Hulst M., De Wolf J.T., et al. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 15 (2005) 379-387
99. Moeremans K., Warie H., and Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 16 (2006) 17-30
100. Trannoy L.L., Lagerberg J.W., Dubbelman T.M., et al. Positively charged porphyrins: A new series of photosensitizers for sterilization of RBCs. Transfusion 44 (2004) 1186-1196
101. Trannoy L.L., Terpstra F.G., de K.D., et al. Differential sensitivities of pathogens in red cell concentrates to Tri-P(4)-photoinactivation. Vox Sang 91 (2006) 111-118
102. Wagner S.J., Skripchenko A., Salata J., et al. Photoinactivation of Leishmania donovani infantum in red cell suspensions by a flexible thiopyrylium sensitizer. Vox Sang 91 (2006) 178-180
103. Skripchenko A., Balch A., Mackin A., et al. In vivo recovery and survival of red cells after photodynamic treatment with thiopyrylium and red light using a canine model. Vox Sang 92 (2007) 157-159
104. Skripchenko A., Wagner S.J., Thompson-Montgomery D., et al. Thiazole orange, a DNA-binding photosensitizer with flexible structure, can inactivate pathogens in red blood cell suspensions while maintaining red cell storage properties. Transfusion 46 (2006) 213-219
105. O'Brien S.F., Yi Q.L., Fan W., et al. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 47 (2007) 316-325
106. Kuhn T.S. The structure of scientific revolutions. 2nd enlarged ed. (1970), The University of Chicago Press, Chicago